key: cord-0688201-pb55s4yw authors: Burgener, Sebastian; Rochat, Philippe; Dollenmaier, Günter; Benz, Gabriel; Kistler, Andreas D.; Fulchini, Rosamaria title: Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review date: 2022-02-25 journal: Case Rep Infect Dis DOI: 10.1155/2022/8712424 sha: 3b97125770f0c176fb5963257aa674c2c5034298 doc_id: 688201 cord_uid: pb55s4yw Accumulating evidence suggests that anti-CD20 treatments are associated with a more severe course of COVID-19. We present the case of a 72-year-old woman treated with the B-cell-depleting anti-CD20 antibody rituximab for seropositive rheumatoid arthritis with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing a clinical relapse more than 4 weeks after the first manifestation. Persistently positive reverse transcription polymerase chain reaction (RT-PCR) results along with a drop in cycling threshold (Ct) values, in addition to recovery of identical viral genotype by whole genome sequencing (WGS) during the disease course, argued against reinfection. No seroconversion was noted, as expected on anti-CD20 treatment. Several other case reports have highlighted potentially fatal courses of COVID-19 associated with B-cell-depleting treatments. Immunocompromised patients are at risk for severe disease courses of COVID-19 and prolonged viral shedding [1] . At the beginning of the pandemic, little was known about COVID-19 patients on anti-CD20 antibody treatment like rituximab, causing prolonged B-cell depletion. However, there is now growing evidence that rituximab is associated with adverse outcomes of COVID-19 infection [2] . Here, we report the intriguing case of a 72-year-old woman receiving rituximab for seropositive rheumatoid arthritis, who experienced a relapsing course of COVID-19. We performed a literature search for case descriptions, including patients with COVID-19 on anti-CD20 antibody treatment. A 72-year-old woman was tested positive for SARS-CoV-2 by RT-PCR in a nasopharyngeal swab on the 4 th of February 2021. Her past medical history was remarkable for seropositive rheumatoid arthritis and connective tissue diseaseassociated interstitial lung disease, for which she received rituximab treatment biannually. Five months before COVID-19 onset, she had received her last dose. Other comorbidities included pulmonary arterial hypertension, coronary artery disease, and atrial fibrillation. At the early stage of the national vaccination campaign, our patient had not been vaccinated. Twelve days later, she was hospitalized in another hospital due to respiratory failure. In addition to the known interstitial lung disease, chest computed tomography revealed new bilateral ground glass opacities consistent with COVID-19 infiltrates. e patient received supplemental oxygen, dexamethasone, and a 10-day course of remdesivir. Following her gradual improvement, a nasopharyngeal SARS-CoV-2 antigen test turned out negative on day 22 and follow-up Ct values of RT-PCR were increasing; thus, isolation precautions were stopped. On day 27, the patient was discharged to inpatient pulmonary rehabilitation. irty-three days after diagnosis, she was admitted to our hospital because of relapsing dyspnea, productive cough, and fever, along with respiratory failure requiring nasal high-flow oxygen therapy and intensive care monitoring. Differential diagnoses included bacterial pneumonia, reinfection with a SARS-CoV-2 mutant, or a relapse of preexisting COVID-19. Inflammatory markers were again elevated, and a computed tomography scan was unchanged (Table 1) . We started treatment with broad-spectrum antibiotics, but sputum analysis and Legionella antigen in the urine were negative. Further invasive measures like mechanical ventilation were not pursued, according to the patient's wishes. 35 days after the first positive RT-PCR test, the patient died from worsening respiratory failure. Autopsy revealed acute diffuse alveolar damage with hyaline membranes due to COVID-19 in addition to underlying interstitial lung fibrosis. Follow-up of Ct values of RT-PCR during the second course of disease showed a clear drop, which was indicative of a recurrence of previous COVID-19 ( Figure 1 ). To rule out reinfection by a mutant, we performed whole genome sequencing of SARS-CoV-2 of the first and last nasopharyngeal swab isolates (days 0 and 35, respectively). Viral genotypes showed identical sequence patterns, and mutational analysis for N501Y and E484K was negative. Furthermore, SARS-CoV-2 serology was not able to detect IgG or IgM antibodies. ese findings led to the conclusion that our patients' clinical deterioration was due to a prolonged and relapsing course of COVID-19. Our literature review showed accumulating evidence for variable clinical courses of COVID-19 in patients with functional B-cell immunodeficiency due to treatment with rituximab ( Table 2) . Reported patients mostly suffered from hemato-oncological or rheumatological comorbidities as an indication for rituximab treatment. Prolonged shedding of SARS-CoV-2 in nasopharyngeal swabs along with either a benign or adverse outcome is a notable feature, independent of the underlying disease. To our knowledge, only one case report has provided whole genome sequencing to rule out reinfection during a prolonged clinical course [2] . is was an important differential diagnosis in our case, since our patient's clinical worsening occurred during the epidemiological situation of a nationwide third wave of COVID-19 with upcoming variants of concern. e substantial drop in Ct values during the second course of disease could not be explained by preanalytical sampling differences [18] , and reinfection was ruled out by genetically identical viral variants of the first and last isolate. A possible hypothesis explaining the initial decrease in viral load, based on in vitro data but not confirmed by clinical studies [19, 20] , could be that remdesivir reduced viral replication, but after stopping antiviral treatment, viral clearing was not possible due to an insufficient antibody response and reemerging viral replication led to a clinical relapse. e potentially severe COVID-19 course under rituximab suggests that, in addition to cellular immunity, humoral immunity plays an important role. erefore, monitoring of immunocompromised patients with B-cell depletion after stopping antiviral treatment is crucial, and repeat quantitative RT-PCR, in addition to clinical assessment, might be useful to detect re-emerging viral replication and infectivity. Our single case description may not be generalizable to other immunocompromised populations. However, cases with relapsing and prolonged courses have been attributed to reduced viral clearance due to the lack of anti-SARS-CoV-2 antibody production by prolonged B-cell depletion after anti-CD20 therapy, as was the case in our patient [3, 5, 7, 10, 17] . is case also highlights the infection control challenges in the handling of this special population with persistent shedding of potentially viable virus. In conclusion, caution should be taken in patients with anti-CD20 antibody treatment, as they can acquire SARS- Consent was obtained from the patient's husband. e authors declare that there are no conflicts of interest. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient e longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient-a case study Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia Persistence and evolution of SARS-CoV-2 in an immunocompromised host Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab Prolonged course of COVID-19-associated pneumonia in a B-cell depleted patient After rituximab Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood B cells due to rituximab treatment Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient COVID-19 in a patient treated for granulomatosis with polyangiitis: persistent viral shedding with No cytokine storm To interpret the SARS-CoV-2 test, consider the cycle threshold value Remdesivir against COVID-19 and other viral diseases Early remdesivir to prevent progression to severe covid-19 in outpatients